Laxxon is a pharma-technology company pioneering a new generation of advanced pharmaceuticals with SPID®, a novel 3D screen printing platform technology. From common pharmaceutical drugs to new drug developments, SPID® unlocks innovative drug delivery advancements paired with fast-tracked market access and extensive IP protection to yield disruptive opportunities for partners, healthcare providers, and patients. Laxxon’s diverse product pipeline is continuously growing and consists of 13 in-house Advanced Patented Generics, in addition to multiple ongoing working-projects with notable pharmaceutical players, biotech organizations and research universities.